Non-alcoholic Steatohepatitis Biomarkers Market

Report Description
Table of Contents

Report Description

The global non-alcoholic steatohepatitis biomarkers market size is estimated to be USD 537.1 million in 2021 and is expected to witness a CAGR of 31.89% during the forecast period. Increasing prevalence of chronic diseases such as heart disease, cancer, and diabetes is a key driver for the growth of the global non-alcoholic steatohepatitis biomarkers market. Additionally, demand for non-invasive diagnostics methods for NASH biomarkers, rising investment by government and private organizations in R&D for NASH biomarkers therapeutics are some of the other drivers propelling the market growth. Nevertheless, side-effects and risks associated with NASH therapeutics and the high cost of technology are expected to restrain the global market growth.

Global Non-alcoholic Steatohepatitis Biomarkers Market Size (USD Million), 2021-2029

Source: Erevna Healthcare

By Type

Based on type, the market is segmented into hepatic fibrosis biomarkers, serum biomarkers, oxidative stress biomarkers, apoptosis biomarkers, and other types. In 2021, the serum biomarkers segment accounted for a substantial revenue share and is expected to grow with a profitable CAGR during the forecast period. This is attributed to associated benefits of serum biomarkers such as the ability to distinguish simple steatosis from NASH and efficient outcomes worldwide. Oxidative stress biomarkers segment is projected to grow at a profitable CAGR during the forecast period. This is attributed to the growth in incidence of diabetes & obesity globally and the improvement in awareness of NASH in developing regions.

By End User

Based on end user, the market is segmented into hospitals, pharma & CRO Industry, diagnostics labs, and academic research institutes. In 2021, the pharma & CRO Industry segment accounted for a substantial revenue share and is expected to grow with a profitable CAGR during the forecast period. This is attributed to the growing demand for non-invasive NASH diagnostic & monitoring tools in the ongoing clinical trials by CROs and pharmaceutical manufacturers can be attributed to its strong growth worldwide. The hospitals segment is projected to grow at a profitable CAGR during the forecast period. This is attributed to increasing in funding to hospitals by the government as well as private players to conduct research on non-alcoholic steatohepatitis biomarkers.

Regional Insights

In 2021, North America accounted for the highest revenue share in the global market and is expected to maintain its dominance during the forecast period. This is attributed to the favorable government initiatives regarding technological development of biomarkers and rising prevalence of infectious and chronic diseases, cardiovascular diseases, & cancer in the region. Asia Pacific market is projected to grow at the fastest CAGR over the forecast period owing to the large population base, improved medical facilities, and presence of huge future growth opportunities in this region.

Competitor Insights

Some of the major companies in the non-alcoholic steatohepatitis biomarkers market GENFIT (France); Gilead (U.S.); AstraZeneca (U.K.); Novartis AG (Switzerland); Bristol-Myers Squibb (U.S); Allergan Novo Nordisk A/S (Ireland); Boehringer Ingelheim GmbH (Germany); Pfizer, Inc. (U.S.); Cadila Healthcare Ltd. (India); and Conatus Pharmaceuticals, Inc. (U.S.). Investment in R&D, novel product launches, and strategic collaborations & acquisitions are some of the major strategies adopted by the leading players operating in the industry.

This exhaustive research report focuses on market size and forecast at global, segmental, regional and country level along with key market trends and dynamics from 2021 to 2029. The non-alcoholic steatohepatitis biomarkers market report is categorized into the following segments and subsegments: